2 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
| Phase 1 | 1 | Terminated 1 |
Follow Interleukin-8: new trials by email Literature Review of Interleukin-8 trials Research Report on Interleukin-8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BMS-986253 in Myelodysplastic Syndromes Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253 - Myelodysplastic Syndromes | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2022-11-29 | 2025-09-30 |
| A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function Ladarixin, Placebo - Recent Onset type1 Diabetes | Phase 2 | Terminated | Dompé Farmaceutici S.p.A | 289 | 2021-01-12 | 2026-08-31 |
Cytopenia (1) · Myelodysplastic Syndromes (1)
Dompé Farmaceutici S.p.A (1) · National Cancer Institute (NCI) (1)
United States (2) · Belgium (1) · Georgia (1) · Germany (1) · Israel (1) · Italy (1) · Serbia (1) · Slovenia (1)